Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-UP: Anamorelin in Postoperative Upper Gastrointestinal Cancer Patients
jRCTs051240256Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of anamorelin in gastric cancer (GC) and esophageal cancer (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Rate of change in lean body mass at postoperative three months. Started Feb 2025; status: active, not recruiting.
02
Drugs
anamorelin
03
Conditions
gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on jRCTs051240256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240256.